Cargando…

New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19

Remdesivir was recently approved by the Food and Drug Administration for the treatment of hospitalized patients with coronavirus disease 2019 (COVID-19). Remdesivir is the prodrug of an adenosine analogue that inhibits viral replication of several RNA virus families, including Coronaviridae. Preclin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aleissa, Muneerah M., Silverman, Emily A., Paredes Acosta, Luisa M., Nutt, Cameron T., Richterman, Aaron, Marty, Francisco M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2020
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927874/ https://www.ncbi.nlm.nih.gov/pubmed/33139290 http://dx.doi.org/10.1128/AAC.01814-20

Ejemplares similares

Placing the results of the SOLIDARITY trial with regards to remdesivir in perspective
por: Bose, Debdipta, et al.
Publicado: (2021)

New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19
por: Atmar, Robert L., et al.
Publicado: (2022)

Indirect Protection by Reducing Transmission: Ending the Pandemic With Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination
por: Richterman, Aaron, et al.
Publicado: (2021)

Postmarketing pharmacovigilance: Remdesivir and cardiovascular events
por: Sullivan, John T.
Publicado: (2022)

1399. Clarithromycin–Rifampin-based Treatment for Non-tuberculous Mycobacterial Infections in Immunocompromised Patients Who Require Concomitant CYP-Metabolized Medications
por: Gonzalez-Bocco, Isabel H, et al.
Publicado: (2021)

1024. Evaluation of Atovaquone Prescribing for Pneumocystis jiroveci Pneumonia (PJP) Prophylaxis
por: Aleissa, Muneerah, et al.
Publicado: (2019)

What Do We Know About Remdesivir Drug Interactions?
por: Yang, Katherine
Publicado: (2020)

Should remdesivir be recommended in France in the early stage of COVID-19
por: Martin, Martinot
Publicado: (2022)

Antimicrobial Use and Antimicrobial Resistance: A Population Perspective
por: Lipsitch, Marc, et al.
Publicado: (2002)

Remdesivir: Remedy the world is waiting for?
por: Suranagi, Umesh Devappa, et al.
Publicado: (2020)

Caution About Truncation-By-Death in Clinical Trial Statistical Analysis: A Lesson from Remdesivir
por: Deng, Yuhao, et al.
Publicado: (2021)

Clarithromycin–Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients who Require Concomitant CYP-Metabolized Medications
por: Gonzalez-Bocco, Isabel H, et al.
Publicado: (2021)

329. Vancomycin area under the concentration-time curve monitoring from Bayesian modeling in outpatient parenteral antimicrobial therapy
por: Gillett, Eric M, et al.
Publicado: (2023)

Targeting of Regulators as a Promising Approach in the Search for Novel Antimicrobial Agents
por: Roncarati, Davide, et al.
Publicado: (2022)

Convergence of Mortality Rates among Patients on Antiretroviral Therapy in South Africa and North America
por: Binagwaho, Agnes, et al.
Publicado: (2014)

The Relationship Between Antibiotic Agent and Mortality in Patients With Febrile Neutropenia due to Staphylococcal Bloodstream Infection: A Multicenter Cohort Study
por: Aleissa, Muneerah M, et al.
Publicado: (2022)

Remdesivir for Early COVID-19 Treatment of High-Risk Individuals Prior to or at Early Disease Onset—Lessons Learned
por: Dölken, Lars, et al.
Publicado: (2021)

The dawn of repurposing vitamins as potential novel antimicrobial agents: A call for global emergency response amidst AMR crisis
por: Max, Baraka L., et al.
Publicado: (2023)

The gold complex auranofin: new perspectives for cancer therapy
por: Abdalbari, Farah H., et al.
Publicado: (2021)

Osmotic Tubulopathy in a Patient With COVID-19 Treated With Remdesivir
por: Wongboonsin, Janewit, et al.
Publicado: (2021)

186. Evaluating Clinical Outcomes for Treatment of Staphylococcal Bloodstream Infection in Patients with Febrile Neutropenia
por: Aleissa, Muneerah M, et al.
Publicado: (2021)

Antibiotics and antimicrobial resistance in the COVID-19 era: Perspective from resource-limited settings
por: Lucien, Mentor Ali Ber, et al.
Publicado: (2021)

Antimicrobial Peptides and Their Analogs: Searching for New Potential Therapeutics
por: Midura-Nowaczek, Krystyna, et al.
Publicado: (2014)

Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma
por: Little, Jessica S., et al.
Publicado: (2022)

Optimization and Control of Agent-Based Models in Biology: A Perspective
por: An, G., et al.
Publicado: (2016)

Can changing the prodrug moiety in remdesivir be a life-saving strategy in COVID-19 infection?
por: Prabha, Praisy K., et al.
Publicado: (2023)

Ivermectin (IVM) Possible Side Activities and Implications in Antimicrobial Resistance and Animal Welfare: The Authors’ Perspective
por: Piras, Cristian, et al.
Publicado: (2022)

Minimizing Risks of Antimicrobial Resistance Development in the Environment from a Public One Health Perspective
por: Zhang, Yu, et al.
Publicado: (2022)

Environmental surveillance of antimicrobial resistance (AMR), perspectives from a national environmental regulator in 2023
por: Hart, Alwyn, et al.
Publicado: (2023)

Oleanolic acid: a promising neuroprotective agent for cerebral ischemia
por: Caltana, Laura, et al.
Publicado: (2015)

A New Venue for the Director’s Perspective
por: Schwartz, David A.
Publicado: (2007)

The Need for Improved Therapeutic Approaches to Protect the Cornea Against Chemotoxic Injuries
por: McNutt, Patrick M., et al.
Publicado: (2020)

Illegal Drugs Laws: Clearing a 50-Year-Old Obstacle to Research
por: Nutt, David
Publicado: (2015)

The Central Dogma Decentralized: New Perspectives on RNA Function and Local Translation in Neurons
por: Holt, Christine E., et al.
Publicado: (2013)

Use of biologically synthesized antimicrobial nanoparticles for improving peritoneal dialysis technique: a translational research perspective
por: Kumar, Dinesh
Publicado: (2016)

Translational perspective: is cinnamon a suitable agent for cognitive impairment and Alzheimer’s disease associated with brain trauma?
por: Yulug, Burak, et al.
Publicado: (2019)

A New Hope in the Fight Against Antimicrobial Resistance with Artificial Intelligence
por: Tran, Minh-Hoang, et al.
Publicado: (2022)

Molecular Recognition: Perspective and a New Approach
por: Seitz, W. Rudolf, et al.
Publicado: (2021)

New Perspectives on Chronic Obstructive Pulmonary Disease
por: Celli, Bartolome R, et al.
Publicado: (2022)

Immunothrombosis: Molecular Aspects and New Therapeutic Perspectives
por: Marcos-Jubilar, María, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nkq44d9rvt0bnrd21vbgdfpupo